SCHEMBL7906323

SCHEMBL7906323

CCc1cc(C(=O)O)c(NC(=O)c2ccc(C(C)(C)C)cc2)s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2C Q14957 6/20 1.00
ALDH1A1 P00352 7/20 0.60
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
MAPT P10636 8/20 0.57
KDM4E B2RXH2 5/20 0.57
RAB9A P51151 3/20 0.57
POLB P06746 1/20 0.57
HPGD P15428 3/20 0.50
GAA P10253 2/20 0.50
SERPINE1 P05121 1/20 0.50
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
MITF O75030 1/20 0.48
KLF5 Q13887 1/20 0.48
NPC1 O15118 2/20 0.47
PTPN5 P54829 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7904197 0.83 GRIN2C (0.70) GRIN2CALDH1A1MEN1KMT2AMAPT
SCHEMBL3589208 0.76 GRIN2C (0.61) GRIN2CALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7889265 0.75 GRIN2C (0.60) GRIN2CALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL6317837 0.75 ALDH1A1 (0.60) GRIN2CALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5554897 0.75 ALDH1A1 (0.60) GRIN2CALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL13727690 0.73 ALDH1A1 (0.73) GRIN2CALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7888439 0.73 GRIN2C (0.57) GRIN2CALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7902807 0.72 NPSR1 (0.61) GRIN2CALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL13431200 0.72 ALDH1A1 (0.66) GRIN2CALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7890829 0.72 GRIN2C (0.56) GRIN2CALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10273214-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions EMORY UNIVERSITY (US) 2019-04-30 US disclosed
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS TRAYNELIS STEPHEN F (US) 2014-09-18 US disclosed
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS TRAYNELIS STEPHEN F (US) 2014-09-18 US disclosed
US-8822462-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions EMORY UNIVERSITY (US) 2014-09-02 US disclosed
US-8822462-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions EMORY UNIVERSITY (US) 2014-09-02 US disclosed
US-20120028977-A1 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions EMORY UNIVERSITY (US) 2012-02-02 US disclosed
US-20120028977-A1 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions EMORY UNIVERSITY (US) 2012-02-02 US disclosed
WO-2010088414-A2 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS EMORY UNIVERSITY (US) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10273214-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions GRIN1, GRIN2A, GRIN2B GRIN2C 5/4885ALDH1A1 2048/4885MEN1 4250/4885
US-20120028977-A1 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions GRIN1, GRIN2A, GRIN2B GRIN2C 5/4885ALDH1A1 2048/4885MEN1 4250/4885
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS GRIN1, GRIN2A, GRIN2B GRIN2C 5/4885ALDH1A1 2048/4885MEN1 4250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.